Conference Proceedings
PF568 INVESTIGATING MECHANISMS OF ELOTUZUMAB AND LENALIDOMIDE THERAPY IN MULTIPLE MYELOMA
KJ Richardson, M Robbins, NA Bezman, H Quach, SJ Harrison, MH Prince, DS Ritchie, MR Jenkins, PA Beavis, PK Darcy, PJ Neeson
HemaSphere | Wiley | Published : 2019
Abstract
Background:Multiple myeloma (MM) is currently incurable. To investigate new treatment options, patients with refractory relapsed (RR) MM were treated with combination of Elotuzumab (Elo, anti‐SLAMF7 antibody) and Lenalidomide (Len, IMiD) and had a 84% objective response rate. We hypothesized this Elo+Len clinical efficacy was due to repair of NK dysfunction in MM patient NK cells.Aims:To explore the mechanisms whereby Elo+Len rescued MM patient NK cell function.Methods:We co‐cultured MM patient PBMCs with myeloma cells and drug combinations in vitro, and compared changes in NK cell activation, cytotoxicity, cytokine/chemokine levels, and adhesion molecule expression between healthy donor (HD..
View full abstract